Heart failure – statins in the light of the CORONA study
Authors:
J. Vítovec 1,2; J. Špinar 1,2
Authors‘ workplace:
I. interní kardioangiologická klinika LF MU
1; FN u sv. Anny v Brně
2
Published in:
Kardiol Rev Int Med 2008, 10(3): 119-122
Overview
Statins are nowadays routinely recommended for prescription in ischemic heart disease. Whether they also improve the prognosis of patients with heart failure of ischemic origin is not yet known. We present a summary of the potential positive and negative effects of statins in patients with heart failure and subsequently analyse the results of the CORONA study. Although the results of this study did not prove a reduction in mortality as a result of treatment using rosuvastatin, there was a significant reduction in the number of hospitalizations from overall cardiovascular causes and from more severe heart failure. Given its minimal undesirable side effects and the improvement in the quality of life, further studies of the use of statins in heart failure would be desirable.
Key words:
statins – heart failure – CORONA study
Sources
1. Anker SD, Clark AL, Winkler R et al. Statin use and survival in patients with chronic heart failure: results from two observational studies with 5.200 patients. Int J Cardiol 2006; 112: 234–342.
2. Hanna IR, Heeke B, Bush H et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3: 881–886.
3. Hargreaves IP. Ubiquinone: cholesterol’s reclusive cousin. Ann Clin Biochem 2003; 40: 207–218.
4. Hradec J. Má význam podávání statinů u nemocných se srdečním selháním? Interní Med 2008; 10: 216–218.
5. Hradec J. Klinická studie CORONA. Remedia 2005; 15: 169–171.
6. Keith M, Geranmayegan A, Sole MJ et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352–1356.
7. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005; 7: 1059–1691.
8. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
9. Krum H, Tonkin A. The Rosuvastatin Impact on Ventricular Remodeling, Cytokines and Neurohormones (UNIVERSE) Study (abstr). J Am Coll Cardiol 2006; 47: 61A–2A.
10. Landmesser U, Spiekermann S, Dikalov S et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106: 3073–3078.
11. Maack C, Kartes T, Kilter H et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567–1574.
12. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999; 100: 999–1008.
13. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004; 363: 892–894.
14. Nickenig G, Bäumer AT, Temur Y et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131–2134.
15. Ramasubbu K, Estep J, White DL et al. Experimental and clinical basis for the use of statins in kardiol with ischemic and nonischemic cardiomyopathy. J Am Coll kardiol 2008; 5: 415–426.
16. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930–933.
17. Sola S, Mir MQ, Lerakis S et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332–337.
18. Soška V. Farmakologie hyperlipoproteinémií. Vnitr Lek 2000; 46: 565–568.
19. Špinar J. et al. Klinické studie v kardiologii. Grada Publishing 2001.
20. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
21. Torre-Amione G, Kapadia S, Benedict C et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201–1206.
22. Tousoulis D, Antoniades C, Vassiliadou C et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005; 7: 1126–1132.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2008 Issue 3
Most read in this issue
- Heart failure with normal ejection fraction
- Catheter ablation of atrial fibrillation
- Comparison of differences between male and female patients with acute myocardial infarction
- Aerobic capacity in patients with ischemic heart disease